| | Pain | | | A Clinical Conversation: Diagnosis & Treatment of Neuropathic Pain
Overview
Four million people in the United States suffer from neuropathic pain, a condition that is often difficult to diagnose. This session, Clinical Conversation: Diagnosis & Treatment of Neuropathic Pain will address practical ways primary care physicians can improve recognition and treatment of neuropathic pain.
Objectives
Faculty
| | | Zoster Virus | | | Preventing Herpes Zoster and Postherpetic Neuralgia: Are Your Patients Adequately Protected?
Overview
An estimated 1 million cases of herpes zoster (shingles) occur annually in the United States. The incidence and severity of herpes zoster increase with advancing age to produce substantial negative effects on quality of life, activities of daily living, neuropsychological functioning, and social status, resulting in significant morbidity in older adults. While antiviral therapy reduces the incidence and severity of herpes zoster, it does not reliably prevent postherpetic neuralgia (PHN), the most common and debilitating clinical sequela of herpes zoster. Herpes zoster vaccination has been demonstrated to reduce the incidence of the disease and its complications. Clinical trial data have demonstrated significant reductions in the incidence of herpes zoster and PHN, as well as overall reductions in the burden of disease.
Objectives
Review the epidemiology and public health burden of herpes zoster and its most common complication, postherpetic neuralgia (PHN)
Discuss the benefits and limitations of current pharmacotherapies for herpes zoster and Postherpetic neuralgia (PHN), and evaluate clinical trial data on the efficacy and safety of herpes zoster vaccination
Faculty
Malcolm Fraser, MD, CMD
President, Bay Geriatrics
St. Petersburg, FL
John W. Gnann, Jr., MD
Professor of Medicine, Pediatrics, and Microbiology
Department of Medicine, Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham VA Medical Center
Birmingham, AL
| | | HPV | | | Reducing the Burden of HPV-Related Diseases: Cervical Cancer and Beyond
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. Prevention of HPV infection through prophylactic vaccination provides a safe and effective option to reduce the health burden associated with HPV-related diseases. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection; provide an update on the safety and efficacy of HPV vaccines, including recent data on efficacy in mid-adult women, duration of protection, and cross-protection against nonvaccine HPV types; and evaluate the benefits of widespread HPV vaccination in preventing HPV-related diseases.
Objectives
Describe the epidemiology, natural history and consequences of HPV infection
Evaluate the anticipated benefits of widespread HPV vaccination in preventing cervical and anogenital cancers, genital warts, and other HPV-related diseases
Faculty
Gregory Brotzman, MD
Professor of Family and Community Medicine
Medical College of Wisconsin
Milwaukee, WI
Daron G. Ferris, MD
Professor
Department of Family Medicine
Department of Obstetrics and Gynecology
Director, Gynecologic Cancer Prevention Center
Medical College of Georgia
Augusta, GA
| | | Acne / Actinic Keratosis | | | More Than Skin Deep: Clinical Strategies for Acne Vulgaris and Actinic Keratosis
Overview
ÒMore Than Skin Deep: Clinical Strategies for Acne Vulgaris and Actinic KeratosisÓ is a continuing medical education program that aims to bridge some of the existing professional practice gaps that primary care clinicians may have regarding common dermatologic problems. This program will educate clinicians in the primary care setting about the prevalence, impact, diagnosis, and treatment of both acne vulgaris and actinic keratosis.
Objectives
Confidently diagnose patients presenting with the basic dermatologic conditions of acne vulgaris and actinic keratosis
Identify the most commonly used treatments for acne vulgaris and actinic keratosis
Faculty
Brian Berman, MD
Professor of Dermatology and Cutaneous Surgery
University of Miami
Miami, FL
Paul J. Honig, MD
Emeritus Professor of Pediatrics and Dermatology
The Children's Hospital of Philadelphia
Philadelphia, PA
| | | Chronic Constipation | | | Up-to-the-Second Advances in the Primary Care Management of Chronic Constipation and Other Functional Bowel Disorders
Overview
Chronic Constipation is a multi-symptom gastrointestinal motility disorder that negatively impacts the lives of approximately 33 million Americans. Due to the overlap in symptoms reported by patients with irritable bowel syndrome-constipation and chronic constipation, clinicians often find it challenging to differentiate between the two. With a changing landscape of therapeutic options available, it is imperative that clinicians be able to establish and accurate diagnosis so the proper foundation is provided for determining initial therapy and developing a treatment plan.
Objectives
Differentiate chronic constipation from other functional bowel disorders
Identify the therapies that can be used to treat chronic constipation and other functional bowel disorders
Faculty
David A. Peura, MD
Professor of Medicine
University of Virginia Health Sciences Center
Charlottesville, VA
John Johanson, MD, MS
Clinical Associate Professor
University of Illinois College of Medicine
Rockford, IL
| | | Menstrual Migraine | | | A Practical Approach to Managing Menstrual Migraine: Tailoring Treatment and Individualizing Care
Overview
Migraine is a chronic, debilitating disorder that affects approximately 28 million Americans of whom ~18% are women and ~6% are men. When compared to migraines that occur during other times of the month, menstrual migraine (MM) may last longer and be more severe, disabling, frequent, and more difficult to treat. This program will address the new advances in the understanding of MM, the role of hormones, and how to select an appropriate treatment based on individual patient characteristics.
Objectives
Recognize migraine in the differential diagnosis of headaches that impact patients ability to fully function in their daily activities and identify menstrual migraine in female patients
Identify management strategies for women with menstrual migraine including use of headache calendars, behavioral modifications and approaches to acute and preventive treatment
Faculty
James A. Voirin, DO, FAAFP
Department of Family Medicine
Physician Associates LLC
Orlando, FL
Norman Gordon, MD
Chief of the Division of Neurology, Miriam Hospital
Clinical Associate Professor of Neurology, Brown University
Medical Director, CNS Research Inc.
Providence, RI
| | | Dyslipidemia | | | The Moving LDL Target: Getting Your Patients to Goal
Overview
The current use of lipid lowering therapy in clinical practice has fallen short of the recommendations of national guidelines. Clearly, not an easy venture when treating patients with dyslipidemia, many with multiple risk factors and many with resulting coronary events that may be preventable if patients were treated aggressively to meet the NCEP-ATP lll goals. This presentation will address the clinical challenges of goal attainment (lack of compliance, aggressive treatment by clinicians, not leaving patients 15 points from goals), and provide clinicians with the pathways and knowledge to help attain their patients to goal.
Objectives
Describe at least two challenges in treating dyslipidemia to NCEP-ATP III goals, implement strategies that will help to assess CHD risk accurately, and get patients to targeted goals
Identify patients at increased risk for cardiovascular events and develop a treatment plan with at least 2 lipid lowering strategies, including the use of multiple therapies, which will help these patients achieve guideline-based targets taking into consideration current lifestyle and pharmacologic treatment options available thus reducing overall cardiovascular risk
Faculty
Robert P. Giugliano, MD, SM
Assistant Professor in Medicine
Harvard Medical School
Boston, MA
John Russell, MD
Clinical Associate Professor of Family and Community Medicine
Temple University School of Medicine
Philadelphia, PA
| | | Insomnia | | | The Face of Insomnia: Risk-benefit Analyses and Pharmacologic Treatment of Insomnia
Overview
This course considers the growing complaint of insomnia in the primary care practice and offers practical approaches to diagnosis and treatment. With the immense importance of sleep, and the need to proactively address insomnia patients in the practice, this course will provide key steps to insomnia management leading to improved patient outcomes and overall health.
Objectives
Describe a patient-centered approach to the diagnosis of insomnia and development of a treatment plan
Apply the elements of a risk/benefit analysis for choosing a pharmacologic option to various patients at risk
Faculty
Rafael Pelayo, MD
Assistant Professor
Stanford University School of Medicine
Stanford, CA
Karl Doghramji, MD
Medical Director, Sleep Disorders Center
Thomas Jefferson University
Philadelphia, PA
| | | Stroke | | | Prevent The Event: Long-term Management of the Stroke Patient
Overview
This lecture will provide a review of epidemiology, acute stroke treatment strategies, overview of the major stroke studies, current stroke treatment guidelines, and global risk reduction strategies. Implementation and patient adherence strategies in the primary care setting will also be discussed.
Objectives
Name the top 3 modifiable risk factors for ischemic stroke
List 4 current treatment recommendations from the AHA/ASA Stroke Guidelines for survivors of ischemic stroke or TIA to prevent future events
Faculty
Howard S. Kirshner, MD
Professor and Vice-Chair, Neurology
Director, Vanderbilt Stroke Center
Vanderbilt University Medical Center
Nashville, TN
Philip Altus, MD, MACP
Professor of Medicine Emeritus
University of South Florida
Tampa, FL
| | | Rheumatoid Arthritis | | | The Triangle of Treatment: Taking a Team Approach to Managing Rheumatoid Arthritis
Overview
Rheumatoid arthritis (RA) is a complex immunologic and chronic inflammatory disease that affects more than 2 million people in the United States. Characterized by inflammation of the joints, periarticular bone resorption and cartilage destruction, RA is also an inherently aggressive, systemic disease that leaves patients vulnerable to comorbidities such as cardiovascular disease, osteoporosis, lymphoma, infection, and stroke. While primary care clinicians may not directly treat the disease long term, they are the first to come in contact with potential RA patients. Therefore it is important for all clinicians to be aware of the necessary steps in RA diagnostic and treatment modalities.
Objectives
Identify 3 early warning signs of rheumatoid arthritis (RA)
Describe current and evolving treatment options for RA, and be alert to monitoring and side effects related to these therapies
Faculty
Arthur Weaver, MD, MS, FACP, MACR
Alvin F. Wells, MD, PhD, FACP, FACR
Director
Rheumatology and Immunotherapy Center
Oak Creek, WI
| | | LUTS | | | Diagnosing and Treating Male Lower Urinary Tract Symptoms (LUTS) in the Primary Care Setting
Overview
Nearly half the male patients over age 50 presenting to the primary care clinician have bothersome lower urinary tract symptoms (LUTS). Identifying and treating LUTS/ benign prostatic hyperplasia (BPH) can be both simple and practical for the PCP. This presentation outlines the first evidence-based algorithm for treating male LUTS created specifically for the needs of primary care clinicians.
Objectives
Identify appropriate treatment for LUTS/BPH based on a focused history and objective measures
Define a strategy to apply techniques and practices to effectively diagnose and initially assess patients with LUTS/benign prostatic hyperplasia (BPH)
Faculty
Richard E. Payne, MD
CEO, North Coast Family Medical Group
Clinical Instructor
Department of Family and Preventative Medicine
University of California, San Diego School of Medicine
La Jolla, CA
Matt T. Rosenberg, MD
| | | Osteoarthritis | | | Optimal Use of Analgesics in the Management of Osteoarthritis Pain
Overview
Optimal Use of Analgesics in the Management of Osteoarthritis Pain will provide an evidence-based, guideline-based review of treatment options for managing osteoarthritis pain. Video-vignette, case-based learning will be used to illustrate education from expert presentations and guidelines. Special emphasis will be placed on physician-patient communication regarding pain management.
Objectives
Implement strategies for patient communication and education for management of OA pain and utilize pharmacologic and nonpharmacologic therapies for pain management according to guideline recommendations
Describe patient risk factors which could interact with various pain relief medications
Faculty
Michael J. Cawley, PharmD
Associate Professor of Clinical Pharmacy
Philadelphia College of Pharmacy
Philadelphia, Pennsylvania
Frank LoVecchio, DO, MPH
Professor
Arizona College of Osteopathic Medicine
Midwestern University
Glendale, Arizona
| | | | | |
Overview
Objectives
Faculty
|
|
